May has just begun, and it's time to turn our attention to the FDA decisions on deck for the coming weeks.So far this year, the U.S. regulatory agency has approved only ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 5.09%, which has investors questioning if this is right time to sell.

Additionally, some infections may exacerbate or trigger psoriasis, such as strep throat. Regardless of whether you are on a biologic or immunosuppressive medication for psoriasis, it’s essential ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

“I am excited to take on the role as CFO as we launch and further commercialize ZORYVE in multiple inflammatory skin conditions and build upon our strong financial position,” said Vairavan. “Having ...

This agreement includes an extension of the 30-month Hatch-Waxman regulatory approval stay, providing Arcutis with continued market exclusivity for its psoriasis treatment, ZORYVE cream 0.3%. Analysts ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15% ...

The insurer argued the policyholder had suppressed the condition of psoriasis in her proposal form and hence was not entitled to the claim. After hearing the arguments, the commission stated ...